Opportunity Information: Apply for RFA AR 18 002
The National Institutes of Health, through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), offered the RFA-AR-18-002 funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01)." It is a discretionary NIH grant mechanism (R01) in the health funding activity category (CFDA 93.846) designed to support time-sensitive mechanistic studies that can be carried out alongside an already active interventional clinical trial. The core idea is to capitalize on an existing trial that is already enrolling or following participants and already has the operational infrastructure in place, rather than building a new cohort or trial from scratch.
The FOA specifically targets ancillary studies that are mechanistic in nature and tied to NIAMS mission areas, meaning research that deepens understanding of biological mechanisms relevant to diseases and conditions within NIAMS' portfolio (for example, arthritis and rheumatic diseases, musculoskeletal disorders, and skin diseases). The ancillary project is expected to leverage what the parent trial already provides: a cohort of well-characterized patients, established trial infrastructure, existing clinical data streams, and access to biological samples (or the ability to collect them within the trial context). By adding a focused mechanistic component to a functioning clinical trial, the NIH aims to extract more scientific value from prior investments and produce insights that might not be achievable through standard clinical endpoints alone.
A defining feature of this opportunity is speed. Applications were intended to go through an accelerated review and award process, reflecting the fact that these ancillary studies are often time-bound. If a parent trial is already underway, there may be a narrow window to add specimen collection, specialized assays, imaging, or other mechanistic measurements before treatment arms conclude, participants roll off, or key timepoints pass. This accelerated pathway is meant to help investigators act while the parent trial can still support the additional work.
In practical terms, the NIH objective here is to provide a flexible mechanism to "piggyback" mechanistic questions onto ongoing interventional trials, thereby maximizing return on existing investments. The ancillary study should enhance the parent project rather than distract from it, adding scientific depth and increasing the overall value of the clinical trial. NIAMS emphasized that successful projects should improve the research community's understanding of disease processes or organ systems relevant to NIAMS, and that the mechanistic findings may point toward new targets for diagnosis, treatment, or prevention. In other words, the ancillary study is expected to help explain why an intervention works or does not work, identify biomarkers or pathways associated with response, clarify disease biology, or otherwise translate clinical trial participation into deeper mechanistic knowledge.
Eligibility was broad and included many common NIH-eligible applicant types: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other organizations. The FOA also highlighted additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, tribal governments that are not federally recognized, and U.S. territories or possessions.
At the same time, the FOA drew clear boundaries around foreign participation. Non-domestic (non-U.S.) entities (foreign institutions) were not eligible to apply as applicant organizations, and non-domestic components of U.S. organizations were also not eligible. However, "foreign components" as defined under the NIH Grants Policy Statement were allowed, meaning a U.S. applicant could include certain types of foreign involvement when it meets NIH policy definitions and requirements, even though a foreign institution could not serve as the primary applicant.
Administrative details included an award ceiling listed as $300,000, with an original closing date of 2018-04-02 and a creation date of 2017-05-01. Overall, the opportunity was structured for investigators who can demonstrate that an existing interventional clinical trial provides the right platform, participants, and operational capacity to support add-on mechanistic research quickly and efficiently, and that the proposed ancillary work will meaningfully expand what can be learned from the parent trial in NIAMS-relevant disease areas.Apply for RFA AR 18 002
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
- This funding opportunity was created on 2017-05-01.
- Applicants must submit their applications by 2018-04-02. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $300,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity described here?
This opportunity is the NIH (NIAMS) Funding Opportunity Announcement (FOA) RFA-AR-18-002 titled "Mechanistic Ancillary Studies to Ongoing Interventional Clinical Trials (R01)." It uses the NIH R01 grant mechanism and is intended to support mechanistic ancillary studies that can be carried out alongside an already active interventional clinical trial.
Which NIH institute is offering this FOA?
The FOA is offered by the National Institutes of Health (NIH) through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
What is the main purpose of this FOA?
The main purpose is to fund time-sensitive, mechanistic studies that "piggyback" on an ongoing interventional clinical trial. The idea is to capitalize on an existing trial that is already enrolling or following participants and already has operational infrastructure in place, rather than creating a brand-new trial or cohort.
What does "mechanistic ancillary study" mean in this context?
In this FOA, an ancillary study is an add-on project that leverages the parent trial's participants, infrastructure, and clinical data streams to answer mechanistic questions (for example, biological mechanisms, pathways, biomarkers, or why an intervention works or does not work). The emphasis is on generating deeper biological or disease-process insight beyond standard clinical endpoints.
Does the parent clinical trial need to be ongoing?
Yes. The FOA is designed specifically for ancillary studies that can be conducted alongside an already active interventional clinical trial that is enrolling participants or following them over time.
Is this FOA meant to fund a new clinical trial?
No. The FOA is intended to add mechanistic research to an existing interventional clinical trial, not to build a new trial or create a new cohort from scratch.
What kinds of studies are considered a good fit?
Studies that can be executed within the narrow time window of an ongoing trial and that add targeted mechanistic measurements, such as specialized assays, imaging, or specimen collection at key timepoints. The project should leverage the parent trial's established infrastructure and participant cohort.
Why does the FOA emphasize speed and time-sensitivity?
Because the parent trial is already underway, there may be limited time to add mechanistic components before participants complete treatment arms, roll off the study, or pass key collection timepoints. The FOA was intended to use an accelerated review and award process to allow investigators to act while the opportunity window is still open.
What is meant by an "accelerated review and award process"?
The FOA stated that applications were intended to move through review and award more quickly than usual, reflecting that these ancillary mechanistic studies are often time-bound and depend on the ongoing trial timeline.
What disease areas does NIAMS consider relevant for this FOA?
The ancillary study must be tied to NIAMS mission areas. Examples mentioned include arthritis and rheumatic diseases, musculoskeletal disorders, and skin diseases. The key expectation is that the mechanistic work deepens understanding of biological mechanisms relevant to NIAMS conditions.
What should the ancillary study leverage from the parent trial?
The FOA expects the ancillary project to leverage what the parent trial already provides, such as:
- A cohort of well-characterized patients
- Established clinical trial infrastructure
- Existing clinical data streams
- Access to biological samples (or the ability to collect them within the trial context)
What types of outputs or insights is NIAMS aiming to get from these ancillary studies?
NIAMS emphasized mechanistic findings that improve understanding of disease processes or organ systems relevant to NIAMS. The ancillary work may help explain intervention response or non-response, identify biomarkers or pathways associated with response, clarify disease biology, or point toward new targets for diagnosis, treatment, or prevention.
How should the ancillary project relate to the parent clinical trial?
The ancillary study should enhance the parent project rather than distract from it, adding scientific depth and increasing the overall value of the clinical trial.
What grant mechanism is used for this opportunity?
This FOA uses the NIH R01 mechanism and is described as a discretionary NIH grant mechanism.
What is the funding activity category and CFDA number listed?
The FOA is in the health funding activity category and lists CFDA 93.846.
What is the award ceiling mentioned for this opportunity?
The administrative details listed an award ceiling of $300,000.
When was this FOA created and when did it close?
The creation date was 2017-05-01, and the original closing date was 2018-04-02.
Who can apply (what types of applicant organizations are eligible)?
Eligibility was described as broad and included many standard NIH-eligible organization types, including:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized tribal governments
- Tribal organizations that are not federally recognized
- Public housing authorities/Indian housing authorities
- Nonprofits (with or without 501(c)(3) status)
- For-profit organizations (other than small businesses)
- Small businesses
- Other organizations
Are minority-serving institutions and community-based organizations included in eligibility?
Yes. The FOA highlighted additional eligible categories such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations, among others.
Are U.S. territories or possessions eligible?
Yes. The FOA explicitly included U.S. territories or possessions among the highlighted eligible applicant categories.
Can a foreign (non-U.S.) institution apply as the primary applicant?
No. Non-domestic (non-U.S.) entities (foreign institutions) were not eligible to apply as applicant organizations.
Can a U.S. organization apply if it has a non-domestic (foreign) component?
No. The FOA stated that non-domestic components of U.S. organizations were also not eligible.
Are any types of foreign involvement allowed at all?
Yes. While foreign institutions cannot be the applicant organization and non-domestic components are not eligible, the FOA allowed "foreign components" as defined under the NIH Grants Policy Statement. This means a U.S. applicant could include certain foreign involvement when it meets NIH policy definitions and requirements.
What is the overarching strategy behind funding these studies?
The strategy is to maximize the return on existing NIH investments by extracting additional mechanistic value from trials that already have participants, operations, and data systems in place.
What makes a proposal compelling under this FOA based on the description provided?
Based on the FOA description, compelling proposals are those that show (1) the parent interventional trial provides the right platform, participants, and operational capacity; (2) the mechanistic work can be added quickly and efficiently; and (3) the ancillary study will meaningfully expand what can be learned from the parent trial in NIAMS-relevant disease areas.
Browse more opportunities from the same category: Health
Next opportunity: Optimizing HIV Phylodynamics to Target and Interrogate Clusters (OPTICs) (R21)
Previous opportunity: Limited Competition: National Swine Resource and Research Center (U42)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AR 18 002
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AR 18 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| Initiation of a Mental Health Family Navigator Model to Promote Early Access, Engagement and Coordination of Needed Mental Health Services for Children and Adolescents (R01) Apply for PAR 17 265 Funding Number: PAR 17 265 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01) Apply for PAR 17 269 Funding Number: PAR 17 269 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Planning Grants for Clinical Trials of High Relevance to the NIGMS Mission (R34) Apply for PAR 17 268 Funding Number: PAR 17 268 Agency: National Institutes of Health Category: Health Funding Amount: $100,000 |
| Pilot Effectivness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R34) Apply for PAR 17 271 Funding Number: PAR 17 271 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01) Apply for PAR 17 272 Funding Number: PAR 17 272 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Modeling of Infectious Disease Agent Study Research Projects (R01) Apply for PAR 17 267 Funding Number: PAR 17 267 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U01) Apply for PAR 17 274 Funding Number: PAR 17 274 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention Infrastructure Resource Access (X01) Apply for PAR 17 277 Funding Number: PAR 17 277 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44) Apply for PAR 17 275 Funding Number: PAR 17 275 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Uncovering the Causes, Contexts, and Consequences of Elder Mistreatment (R01) Apply for RFA AG 18 010 Funding Number: RFA AG 18 010 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21) Apply for PA 17 282 Funding Number: PA 17 282 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R21) Apply for PA 17 284 Funding Number: PA 17 284 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Understanding Processes of Recovery in the Treatment of Alcohol Use Disorder (R01) Apply for PA 17 285 Funding Number: PA 17 285 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Academic Leadership Career Award (K07) Apply for PAR 17 287 Funding Number: PAR 17 287 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25) Apply for PAR 17 290 Funding Number: PAR 17 290 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (U34) Apply for RFA HL 18 008 Funding Number: RFA HL 18 008 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| Behavioral Interventions for Prevention of Opioid Use Disorder or Adjunct to Medication Assisted Treatment-SAMHSA Opioid STR Grants (R21/R33) Apply for RFA AT 18 001 Funding Number: RFA AT 18 001 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) Apply for PAR 17 293 Funding Number: PAR 17 293 Agency: National Institutes of Health Category: Health Funding Amount: $400,000 |
| Catalyzing Innovation in Late Phase Clinical Trial Design and Statistical Analysis Plans (X01) Apply for RFA HL 18 009 Funding Number: RFA HL 18 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Drug Resistance: Genotype-Phenotype-Outcome Correlations (R01) Apply for PA 17 291 Funding Number: PA 17 291 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AR 18 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.